Industry News

Relypsa, Inc., a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company’ s board of directors granted 2 new employees options to purchase an aggregate of 5,700 shares of the company’ s common stock with a per share exercise price of $20.67, the closing trading price on the grant date, and 2,850 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa,..."/>
Relypsa Announces New Employment Inducement Grants
Helix BioPharma Corp., an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that an Agreement in Principle has been reached with the National Research Council of Canada to collaborate on various immuno-oncology initiatives. "Helix has been exploiting a camelid single domain antibody which was previously licenced from NRC and is currently in Phase II clinical studies for non-small cell lung..."/>
Helix BioPharma Corp. Announces Agreement in Principle With National Research Council of Canada to Collaborate on Various Immuno-Oncology Initiatives
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’ s disease, today provided an update..."/>
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Cynapsus Therapeutics, Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’ s disease, today announced..."/>
Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease, today provided an update..."/>
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Cynapsus Therapeutics, Inc., a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease, today announced..."/>
Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2016 financial results on Thursday, August 4, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m./ 1:30 p.m. to discuss the company’ s financial..."/>
Five Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4
Lexicon Pharmaceuticals, Inc. today announced the acceptance of the filing submitted by Ipsen to the European Medicines Agency for telotristat etiprate as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome. "We are pleased with the EMA's acceptance of Ipsen's filing for telotristat etiprate on schedule as we work diligently with FDA in its priority review of our own New Drug Application..."/>
Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Surgical Care Affiliates, Inc. today announced that it will release its second quarter 2016 financial results prior to U.S. financial markets opening on Tuesday, August 2, 2016. In conjunction with the announcement, SCA will host a conference call at 8:00 a.m. Eastern Time on Tuesday, August 2, 2016 to discuss its second quarter 2016 financial and operating results.. The live webcast of SCA’ s quarterly conference call will be available by accessing..."/>
Surgical Care Affiliates, Inc. to Release Second Quarter 2016 Financial Results and Host Conference Call on August 2, 2016
ArQule, Inc. today announced the first public presentation of data on its novel BTK inhibitor, ARQ 531, at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii. ARQ 531 is an investigational, orally bioavailable, potent and reversible Bruton’ s tyrosine kinase inhibitor."/>
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference
Allergan's generics division is underway, with talks taking place with investors in the US and Europe. Teva is due to complete the pricing stage of the bond issue in the next few days, and to raise over $20 billion. Teva originally planned the offering for the fourth quarter-- it has a bridging bank loan that gives it flexibility over the timing-- but brought the timetable forward because of the low interest rate..."/>
Analysts cut Teva price targets [Globes, Tel Aviv, Israel]
Digirad Corporation will release financial results for its second quarter ended June 30, 2016, before the market opens on Thursday, July 28, 2016.. A conference call is scheduled for 11:00 a.m. EDT on July 28, 2016 to discuss the results and management’ s outlook. The call may be accessed by dialing 1-877-407-9039."/>
Digirad Corporation to Release 2016 Second Quarter Financial Results On July 28, 2016
ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced the time of its second quarter 2016 earnings release and conference call.. The Company will release its second quarter 2016 results at approximately 4:00 p.m. EDT and will be conducting a conference call concerning those results at 4:30 p.m. EDT on Monday, August 8,..."/>
ICU Medical, Inc. Announces Time of Second Quarter 2016 Earnings Call
Cerner campus in south Kansas City finally has a name. Cerner executives settled on "Innovations" for what has been called the "Trails" campus located at Interstate 435 and the former Bannister Mall. The name stemmed from surveys, focus groups and company input."/>
Cerner offers a glimpse of new south KC campus, unveils its new name [The Kansas City Star]
Lipocine Inc.. Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 are encouraged to contact the firm in advance of the August 30, 2016 lead plaintiff motion deadline.. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm
Juno Therapeutics Inc.. Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 inclusive, are encouraged to contact the Firm prior to the September 12, 2016 lead plaintiff motion deadline.. If you purchased shares of Juno during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by..."/>
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
Depomed, Inc. today announced the Patent Trial and Appeal Board of the United States Patent and Trademark Office declined to institute the Inter Partes Review petition filed by Rosellini Scientific, LLC with respect to U.S. Patent No. 7,994,364 with respect to all patent claims subject of the petition. The' 364 Patent is listed for the company's NUCYNTA ® and NUCYNTA ® ER products in the FDA's Orange Book. "Safe Harbor" Statement under the..."/>
Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent
Cerner, a global leader in health care technology, today revealed design elements and the new identity for its I-435 and Bannister Road development. The campus will be called Innovations– a testament to the company’ s work and vision.. “This project is a tangible reflection of Cerner’ s growth and the next generation of health care innovations."/>
Cerner Announces Design Features, ‘Innovations’ Name for New Campus
ZIOPHARM Oncology Inc. concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com. No class has been certified in the above action."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of ZIOPHARM Oncology, Inc. and Advises Investors with Losses to Contact the Firm
Eagle Pharmaceuticals Inc. concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here to participate."/>
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. And Reminds Investors with Losses To Contact The Firm

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials723 Articles
Consumer Discretionary635 Articles
Information Technology628 Articles
Industrials468 Articles
Health Care369 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.